Navigation Links
US, European cholesterol guidelines differ in statin use recommendations
Date:3/29/2014

Application of U.S. and European cholesterol guidelines to a European population found that proportions of individuals eligible for statins differed substantially, with one U.S. guideline recommending statins for nearly all men and two-thirds of women, proportions exceeding those of the other guidelines, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions.

The common approach in cardiovascular disease (CVD) primary prevention is to identify individuals at high enough risk to justify more intensive lifestyle interventions, treatment with medications, or both. The CVD prevention guidelines developed by the National Cholesterol Education Program expert panel, the American College of Cardiology/American Heart Association (ACC/AHA) task force, and the European Society of Cardiology (ESC) are the major guidelines influencing clinical practice. "Varying approaches to CVD risk estimation and application of different criteria for therapeutic recommendations would translate into substantial differences in proportions of individuals qualifying for treatment at a population level," the authors write.

Maryam Kavousi, M.D., Ph.D., of Erasmus MC-University Medical Center, Rotterdam, the Netherlands, and colleagues conducted a study to determine population-wide implications of the ACC/AHA, the Adult Treatment Panel III (ATP-III), and the ESC guidelines, using 4,854 Dutch participants from the Rotterdam Study (a population-based study of patients 55 years of age or older). The researchers calculated 10-year risks for "hard" (major) atherosclerotic cardiovascular disease (ASCVD) events (including fatal and nonfatal coronary heart disease [CHD] and stroke) (ACC/AHA); hard CHD events (fatal and nonfatal heart attack, CHD mortality) (ATP-III); and atherosclerotic CVD mortality (ESC). The proportions of individuals for whom statins would be recommended were calculated per guideline.

The average age of the participants was 65.5 years; 54.5 percent were women. The researchers found that application of the ACC/AHA guideline recommended treatment for 96.4 percent of men and 65.8 percent of women; for the ATP-III guideline, the portion was 52 percent of men and 35.5 percent of women; and for the ESC guideline, 66.1 percent of men and 39.1 percent of women were included in the category where treatment was recommended.

With the ACC/AHA approach, average predicted risk vs observed major ASCVD events was 21.5 percent vs 12.7 percent for men and 11.6 percent vs 7.9 percent for women. Similar overestimation occurred with the ATP-III and ESC model.

"Improving risk predictions and setting appropriate population-wide thresholds are necessary to facilitate better clinical decision making," the authors conclude.


'/>"/>

Contact: Maryam Kavousi, M.D., Ph.D.
m.kavousi@erasmusmc.nl
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Better nurse staffing and education reduces patient deaths in European hospitals
2. European Home Healthcare Market (Respiratory Therapy, Rehabilitation Therapy) worth $57.2 Billion by 2017 - New Report by MarketsandMarkets
3. European Anesthesia, Respiratory and Sleep Management Device Market
4. Selexis SA Names Dr. Marco Bocci Director of European Sales and Business Development
5. European Market for Multiparameter Patient Monitoring Solutions
6. 22 million women aged over 50 are affected by osteoporosis in the European Union
7. A*STAR scientist wins European Molecular Biology Organization Young Investigator award
8. European Markets for Dental Prosthetics and CAD/CAM Devices
9. European Market for Remote Patient Monitoring Applications
10. European Food Safety Testing Market (Pathogen, GMO, Toxin, Pesticide) Worth $4,068.8 Million by 2018 - New Report by MarketsandMarkets
11. Ganeden Biotech Announces UK-based Leatherhead Food Research As Its Approved European Testing Lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... FCPX LUT Monochromatic Volume 2 is an ... easily add washed color grades to footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. This pack comes with 60 different ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
(Date:8/21/2017)... ... 21, 2017 , ... Project Hero today announced ... a multi-million dollar partnership commitment to support Project Hero’s efforts to help ... injuries (TBI) over the next year. , Optum’s partnership will help support ...
(Date:8/20/2017)... Texas (PRWEB) , ... August 20, 2017 , ... ... that the HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients ... of Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: